A novel bispecific nanobody protects mice against RSV infection via intranasal administration
Journal of Virology · 2025
DOI: 10.1128/jvi.01285-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Virology, 2025. Verfasst von Min Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, Th…. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Antibodies, Bispecific, Single-Domain Antibodies, Respiratory Syncytial Virus, Human. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: State Key Laboratory of Respiratory Disease.
Abstract (Originalsprache)
Respiratory syncytial virus (RSV) is the leading cause of respiratory infection-related hospitalizations in children younger than 5 years. Neutralizing nanobody-based interventions represent a promising strategy against RSV. Here, we identify a novel nanobody (4-H1) targeting the RSV prefusion F (pre-F) protein, which demonstrates potent neutralization against both RSV A and B subtypes. Epitope characterization via binning assays, molecular docking, and mutational analyses revealed that 4-H1 interacts with a unique region within antigenic site Ø by engaging critical residues L207, K209, and the K65-N67-C69 cluster. To improve the in vivo efficacy and stability of the 4-H1 nanobody, we engineered a heterotrimeric bispecific nanobody (4-H1-anti-HSA-4-H1). This single-chain molecule contains two anti-RSV F nanobody domains and one anti-human serum albumin (HSA) domain, resulting in a trivalent molecule with dual specificity. This construct demonstrated sub-nanogram per milliliter (sub-ng/mL) neutralization potency against both RSV A and B subtypes, with prolonged in vivo half-life. Notably, intranasal administration of this construct before exposure conferred robust protection against RSV challenge in BALB/c mice. These results underscore the potential of 4-H1-anti-HSA-4-H1 as a respiratory-delivered prophylactic against RSV. IMPORTANCE RSV is the leading cause of infant respiratory hospitalizations, highlighting the urgent need for effective prophylaxis. Here, we engineered a potent bispecific nanobody (4-H1-anti-HSA-4-H1) that exhibits exceptional neutralization against both RSV A and B subtypes with prolonged serum persistence. Prophylactic intranasal delivery of this construct conferred robust protection against RSV challenge in mice, indicating its potential as a respiratory-delivered prophylactic candidate against RSV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou…
- Guangzhou National Laboratory, Bio-island, Guangzhou, Guangdong, China.
- Guangzhou Medical University, Guangzhou, Guangdong, China.
ORCID-Profile: Min Zhang
Förderung
- State Key Laboratory of Respiratory Disease
Zitieren
APA
Zhang, M., Qin, L., Guo, R., Li, J., Huang, S., Sheng, C., & Xiang, Y. (2025). A novel bispecific nanobody protects mice against RSV infection via intranasal administration. Journal of Virology. https://doi.org/10.1128/jvi.01285-25
Vancouver
Zhang M, Qin L, Guo R, Li J, Huang S, Sheng C, et al. A novel bispecific nanobody protects mice against RSV infection via intranasal administration. Journal of Virology. 2025. doi:10.1128/jvi.01285-25
BibTeX
@article{Zhang2025,
author = {Zhang, Min and Qin, Liuxing and Guo, Raoqing and Li, Jinwei and Huang, Si and Sheng, Chen and Xiang, Yijia},
title = {A novel bispecific nanobody protects mice against RSV infection via intranasal administration},
journal = {Journal of Virology},
year = {2025},
doi = {10.1128/jvi.01285-25}
}
EUVIMED